Minerals Technologies Inc. (MTX) 66.44 -1.31

Minerals Technologies, Inc.
(MTX) 66.44 -1.31

Last Trade:	65.94	Day Range:	65.86 - 66.94
Trade Time:	04:02PM	52wk Range:	46.17 - 70.675
Prev. Close:	67.25	Market Cap:	1.16B
Open:	66.57	Div Yield:	0.3
Volume:	64961	PE:	180
EPS:	3.73

The Latest On MTX

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest ROE 1/26/12 2:08am

Top 4 NYSE Stocks In The Synthetics Industry With The Highest ROA 12/5/11 3:44am

UPDATE: J.P. Morgan Lowers PT on Minerals Technologies to $65 10/31/11 7:17am

JP Morgan Lowers PT on Minerals Technologies to $65 10/31/11 5:56am

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest ROE 9/19/11 3:17am

Top 4 NYSE Stocks In The Synthetics Industry With The Highest Operating Margin 9/8/11 3:05am

Gabelli Has Buy On Minerals Technologies 8/15/11 7:52am

JP Morgan Reiterates Overweight on Minerals Technologies, Raises PT to $76 8/2/11 7:40am

JP Morgan Raises PT On Minerals Technologies To $76 8/2/11 6:06am

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest Profit Margin 7/12/11 3:09am

Commercial Metals Company Appoints Barbara Smith Chief Financial Officer (CMC) 5/5/11 7:19am

J.P. Morgan Reiterates Overweight Rating And PT On Minerals Technologies (MTX) 5/2/11 8:36am

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest ROE 1/26/12

Top 4 NYSE Stocks In The Synthetics Industry With The Highest ROA 12/5/11

UPDATE: J.P. Morgan Lowers PT on Minerals Technologies to $65 10/31/11

JP Morgan Lowers PT on Minerals Technologies to $65 10/31/11

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest ROE 9/19/11

Top 4 NYSE Stocks In The Synthetics Industry With The Highest Operating Margin 9/8/11

Gabelli Has Buy On Minerals Technologies 8/15/11

JP Morgan Reiterates Overweight on Minerals Technologies, Raises PT to $76 8/2/11

JP Morgan Raises PT On Minerals Technologies To $76 8/2/11

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest Profit Margin 7/12/11

Commercial Metals Company Appoints Barbara Smith Chief Financial Officer (CMC) 5/5/11

J.P. Morgan Reiterates Overweight Rating And PT On Minerals Technologies (MTX) 5/2/11

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest ROE 1/26/12

Top 4 NYSE Stocks In The Synthetics Industry With The Highest ROA 12/5/11

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest ROE 9/19/11

Top 4 NYSE Stocks In The Synthetics Industry With The Highest Operating Margin 9/8/11

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest Profit Margin 7/12/11

Top 4 Small-Cap Stocks In The Synthetics Industry With The Highest Cash (MTX, POL, ARJ, HWKN) 2/10/11

UPDATE: J.P. Morgan Lowers PT on Minerals Technologies to $65 10/31/11

JP Morgan Lowers PT on Minerals Technologies to $65 10/31/11

Gabelli Has Buy On Minerals Technologies 8/15/11

JP Morgan Reiterates Overweight on Minerals Technologies, Raises PT to $76 8/2/11

JP Morgan Raises PT On Minerals Technologies To $76 8/2/11

J.P. Morgan Reiterates Overweight Rating And PT On Minerals Technologies (MTX) 5/2/11

J.P. Morgan raises Minerals Technologies PT To $74 (MTX) 2/7/11

JP Morgan Raises PT On Minerals Technologies To $74 2/7/11

JP Morgan Reduces Estimates On Minerals Technologies 11/1/10

Trade MTX
NOW!

Partner Headlines

Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells ... 11/17/11

Earnings Watch: 10 Chemical Stocks 4/20/11

Minerals Technologies Inc. Reports Operating Results (10-Q)

Press Releases

Chelsea Therapeutics Announces FDA Advisory Committee Meeting Date for Review of NORTHERA(TM) NDA for the Treatment of Symptomatic NOH 1/3/12 GlobeNewswire Story

Chelsea Therapeutics Reports Topline Results From Phase II Trial of Droxidopa in Fibromyalgia 12/22/11 GlobeNewswire Story

UCB Announces Start of the EXXELERATE™ Clinical Study in Rheumatoid Arthritis 12/21/11 Newswire Story

Chelsea Therapeutics Receives Notice of Allowance of Key U.S. Patent for Novel, Controlled Release Formulation of Northera(TM) 12/15/11 GlobeNewswire Story

Chelsea Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference 11/29/11 GlobeNewswire Story

Chelsea Therapeutics Announces FDA Acceptance of NDA for Filing and Designation of Priority Review of NORTHERA(TM) for the Treatment of Symptomatic NOH 11/17/11 GlobeNewswire Story

New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 Was Predictive of Week 52 Response 11/7/11 Business Wire Story

New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-TNF The 11/7/11 Newswire Story

New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11/7/11 Newswire Story

Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA 11/6/11 Newswire Story

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 11/5/11 Newswire Story

Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 11/5/11 Business Wire Story

Get the latest MTX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Minerals Technologies, Inc. stock price.

Minerals Technologies, Inc. by YCharts